Starling Oncology, Inc. (STLNW) Stock Price & Analysis
Starling Oncology, Inc. (STLNW) closed at USD 0.02 on Tuesday, October 13, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.02; the Oct 13, 2026 session ranged USD 0.02–0.02 on volume of 9 shares. Market capitalization is —, with a 52-week range of USD 0.02–0.02 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/STLNW.md
Key facts (STLNW)
- Analysts: None.
Analysts (STLNW)
Consensus None.
Key Statistics (as of October 16, 2026 at 05:49 UTC)
| Price | USD 0.02 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.02 |
| Open | USD 0.02 |
| Day Range | USD 0.02 – 0.02 |
| 52-Week Range | USD 0.02 – 0.02 |
| Volume | 9 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (STLNW)
Wall Street analysts rate STLNW "None", per Nexqual as of October 16, 2026 at 05:49 UTC.
| Consensus Rating | None |
|---|
Earnings (STLNW)
| Revenue Estimate | $168.69M |
|---|
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Financials & Fundamentals (STLNW)
| Total Revenue | $587.24M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +34.60% |
| Gross Margin | +15.69% |
| Operating Margin | -2.86% |
| Profit Margin | -6.18% |
| Current Ratio | 1.36 |
| Total Cash | $41.09M |
| Total Debt | $104.79M |
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Financial Health Score (STLNW)
Nexqual rates Starling Oncology, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:49 UTC.
| Growth | Strong — Revenue +35% YoY (latest Q) |
|---|---|
| Profitability | Weak — Gross margin 16%, operating -3% |
| Balance Sheet | Mixed — $41M cash vs $105M debt |
| Cash Flow | Solid — Operating cash flow $328K (TTM) |
| Efficiency | Mixed — No data |
Ownership (STLNW)
| Float | 88.89M |
|---|
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Leadership (STLNW)
Starling Oncology, Inc. is led by Daniel Virnich FACHE (age 46), CEO & Executive Director, per Nexqual as of October 16, 2026 at 05:49 UTC.
| CEO & Executive Director | Daniel Virnich FACHE (age 46) |
|---|---|
| Chief Financial Officer | Robert Carter (age 39) |
| Senior Vice President of Finance | Stephen Cella |
Major Backers & Investors (STLNW)
Notable institutional backers of Starling Oncology, Inc. include LMR Partners LLP, Deerfield Management Company, L.P, Wolverine Asset Management, LLC, according to Nexqual as of October 16, 2026 at 05:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| LMR Partners LLP | 17.13% |
| Deerfield Management Company, L.P | 13.18% |
| Wolverine Asset Management, LLC | 4.41% |
| Davidson Kempner Capital Management LP | 3.36% |
| Toronto Dominion Bank | 1.98% |
| Oasis Management Co Ltd. | 1.05% |
| Man Group PLC | 0.94% |
| Healthcare of Ontario Pension Plan Trust Fund | 0.92% |
Source: Nexqual, October 16, 2026 at 05:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PIIIW | P3 Health Partners Inc. | USD 0.01 | ▲ 16.67% |
| SKYAW | SkyAI, Inc. | USD 0.06 | ▼ 4.59% |
| JSPRW | Jasper Therapeutics, Inc. | USD 0 | ▼ 84.62% |
| STLN | Starling Oncology, Inc. | USD 6.91 | ▲ 3.13% |
| TMCWW | TMC the metals company Inc. Warrants | USD 0 | ▼ 50% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt